Page 32

Abril_2107

ARTÍCULO DE INVESTIGACIÓN Enfermedad de Basedow Graves en un hospital universitario - A. Lanas et al desde registros de fichas clínicas, por lo que puede existir algún grado de pérdida de información. Podemos concluir que las características de los pacientes controlados con EBG en un centro universitario pueden diferir de las descritas en la literatura, por lo que es importante conocer la casuística local para optimizar los recursos y el trabajo del equipo multidisciplinario que maneja 440 a los pacientes con EBG. Las características particulares de la población que es derivada a un centro de alta complejidad pueden explicar la alta frecuencia de oftalmopatía severa y la mayor tasa de manejo quirúrgico. Referencias 1. Cooper DS. Hyperthyroidism. Lancet 2003; 362: 459-68. 2. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Survey (NHANES III). J Clin Endocrinol Metab 2002; 87: 489- 99. 3. Nyström HF, Jansson S, Berg G. Incidence rate and clinical features of hyperthyroidism in a long-term iodine sufficient area of Sweden (Gothenburg) 2003-2005. Clin Endocrinol (Oxf) 2013; 78 (5): 768-76. 4. B rent GA. Graves’ Disease. N Engl J Med 2008; 358: 2594-605. 5. Wartofsky L, Glinoer D, Solomon B, Nagataki S, Lagasse R, Nagayama Y, et al. Differences and similarities in the diagnosis and treatment of Graves’ disease in Europe, Japan, and the United States. Thyroid 1991; 1: 129-35. 6. Burch HB, Burman KD, Cooper DS. A 2011 Survey of Clinical Practice Patterns in the Management of Graves’ Disease. J Clin Endocrinol Metab 2012; 97: 4549-58. 7. Bartalena L, Baldeschi L, Dickinson AJ, Eckstein A, Kendall Taylor P, Marcocci C, et al. Consensus statement of the European group on Graves’ orbitopathy (EUGOGO) on management of Graves’ orbitopathy. Thyroid 2008; 18 (3): 333-46. 8. López Rodríguez G, Muzzo B. Evolución de la nutrición de yodo en la población chilena. Rev Chil Nutr 2006; 33: 204-6. 9. Weetman AP. Graves´ Disease. N Engl J Med 2000; 343: 1236-48. 10. Bahn RS. Graves’ ophthalmopathy. N Engl J Med 2010; 362 (8): 726-38. 11. Saldías N, Torres G, Cárdenas N, García J. Descompresiones orbitarias en orbitopatía tiroidea ¿Rinden todo lo que nos gustaría? Experiencia de 9 años. Archivos Chilenos de Oftalmología 2016. En prensa. 12. Reddy SV, Jain A, Yadav SB, Sharma K, Bhatia E. Prevalence of Graves’ ophthalmopathy in patients with Graves’ disease presenting to a referral centre in north India. Indian J Med Res 2014; 139 (1): 99-104. 13. Sundaresh V, Brito JP, Wang Z, Prokop LJ, Stan MN, Murad MH, et al. Comparative Effectiveness of Therapies for Graves’ Hyperthyroidism: A Systematic Review and Network Meta-analysis. J Clin Endocrin Metab 2013; 98 (9): 3671-7. 14. Törring O, Tallstedt L, Wallin G, Lundell G, Ljunggren JG, Taube A, et al. Graves’ hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine-a prospective, randomized study. Thyroid Study Group. J Clin Endocrinol Metab 1996; 81 (8): 2986-93. 15. Bahn RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pract 2011; 17 (3): 456-520. 16. Burch HB, Cooper DS. Management of Graves Disease A Review. JAMA 2015; 314 (23): 2544-54. 17. Ma C, Xie J, Wang H, Li J, Chen S. Radioiodine therapy versus antithyroid medications for Graves’ disease. Cochrane Database Syst Rev 2016; 2: CD010094. 18. Acharya SH, Avenell A, Philip S, Burr J, Bevan JS, Abraham P. Radioiodine therapy (RAI) for Graves’ disease (GD) and the effect on ophthalmopathy: a systematic review. Clin Endocrinol (Oxf) 2008; 69 (6): 943-50. 19. Bartalena L. The Dilemma of How to Manage Graves’ Hyperthyroidism in Patients with Associated Orbitopathy. J. Clin. Endocrinol. Metab 2011; 96: 592-9. 20. Phitayakorn R, Morales-García D, Wanderer J, Lubitz CC, Gaz RD, Stephen AE, et al. Surgery for Graves’ disease: a 25-year perspective. Am J Surg 2013; 206 (5): 669-73. 21. Pradeep PV, Agarwal A, Baxi M, Agarwal G, Gupta SK, Mishra SK. Safety and Efficacy of Surgical Management of Hyperthyroidism: 15-year Experience from a Tertiary Care Center in a Developing Country. World J Surg (2007) 31: 306-12. 22. Pineda P, Michelsen H, Rivera M, Lillo R, Massardo T, Araya V, et al. Treatment of hyperthyroidism with radioiodine: effects of administered dose on complications and thyroid function. Rev Med Chile 2000; 128 (5): 499-507. 23. Pineda G, Arancibia P, Mejía G. Treatment of Basedow Graves’ hyperthyroidism: retrospective analysis after 30 years. Rev Med Chile 1998; 126 (8): 953-62. Rev Med Chile 2017; 145: 436-440


Abril_2107
To see the actual publication please follow the link above